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DNase I footprinting has been used to examine the sequence selective binding of ditrisarubicin B, a novel anthracycline 
antibiotic, to DNA. At 37°C no footprinting pattern is observed, the drug protects all sites from enzymic cleavage with 
equal efficiency. At 4°C a footprinting pattern is induced with low drug concentrations which is different from that pro- 
duced by daunomycin. The best binding sites contain the dinucleotide step GpT (ApC) and are located in regions of 
alternating purines and pyrimidines. 
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1. INTRODUCTION 
Ditrisarubicin B is a new member of the an- 
thracycline group of antitumour antibiotics, 
possessing trisaccharides attached to both C7 and 
CI0 of the anthracycline ring [1] (fig. 1). It inhibits 
RNA synthesis at low concentrations [2]and binds 
to calf thymus DNA with an affinity ten times 
greater than the simpler anthracycline daunomycin 
[1]. 
Footprinting studies with daunomycin, perform- 
ed at 4°C to stabilise the drug-DNA complex, have 
suggested that it binds to adjacent GC residues 
which are flanked by an AT base pair [3]. In the 
crystal structure of daunomycin complexed to 
d(CGTACG), drug molecules are intercalated into 
the CpG steps with the daunosamine ring position- 
ed in the DNA minor groove [4]. The structure is 
stabilised by several hydrogen bonds. Theoretical 
calculations [5] suggest that the C9 hydroxyl group 
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is involved in favourable interactions with the 
guanine above, and that the requirement for an AT 
base pair in the third position arises from repulsive 
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Fig.1. Structures of daunomycin (a) and ditrisarubicin B (b). 
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forces which would occur between the daunos- 
amine and the 2-amino group of guanine. 
In order to clarify the importance of these 
residues for the s quence selective binding we have 
performed comparative footprinting studies on 
ditr isarubicin B, which lacks the C13 carbonyl yet 
possesses an additional charged group on the first 
sugar attached to C10. The results show that 
ditr isarubicin B has different sequence recognition 
characteristics to daunomycin.  
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Fig.2. DNase I footprinting of the tyrT and pTyr2 fragments in the absence (con) and presence of ditrisarubicin B (ditris) and 
daunomycin (dau). The concentration of each ligand inmicromolar isgiven above the gel lane. Each set of three lanes corresponds to 
digestion by the enzyme for 1, 5 and 30 min. The tracks labelled 'G' are dimethylsulphate-piperidine markers specific for guanine. 
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2. MATERIALS  AND METHODS 
2.1. Antibiotics and enzymes 
Ditrisarubicin B was prepared as previously described [1]. 
Daunomycin hydrochloride was purchased from Sigma. 
Because of the unknown aqueous olubility of ditrisarubicin 
both compounds were dissolved in dimethyl sulphoxide 
(DMSO) and diluted to working concentrations in 10 mM Tris- 
HC1, pH 8.0, containing 10 mM NaCI immediately before use. 
The final concentration (always less than 10%) does not in- 
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Fig.3. DNase I footprinting of the 135 and 220 base pair DNA fragments in the absence (con) and presence of ditrisarubicin B (ditris) 
and daunomycin (dau). The concentration f each ligand is given above the gel lanes. Each set of three lanes corresponds to digestion 
by the enzyme for 1, 5 and 30 min. The track labelled 'G' corresponds to a dimethylsulphate-piperidine marker specific for guanine. 
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terfere with the footprinting results and where a direct com- 
parison with previous results for daunomycin is possible the 
footprinting patterns are identical. DNase I was purchased from 
Sigma, stored as a 7200 U/ml solution at - 20°C and diluted to 
appropriate concentrations immediately before use. 
2.2. DNA fragments 
The four DNA fragments were isolated nd labelled as 
previously described [6,7]. The 220-mer and 135-mer were 
prepared from plasmid pXbsl [8] by cutting with HindlII, 
labelling at the 3'-end with [ot32P] dATP, cutting with Sau3A1 
and separating the radiolabelled fragments on a 6070 
polyacrylamide gel. Both the 160 base pair TyrT DNA fragment 
and the 166 base pair ptyr2 DNA fragment were labelled at the 
3'-ends of their EcoRI sites. The fragments were numbered as
previously described. 
2.3. Footprinting 
Low temperature DNase I footprinting was performed as 
previously described [9]. The products of digestion were frac- 
tionated on 8°70 denaturing polyacrylamide gels. Bands in the 
digests were assigned by using Maxam-Gilbert G-specific se- 
quencing lanes, or by comparison with previous DNase I pat- 
terns. 
3. RESULTS 
Footprinting experiments with ditrisarubicin B
at 37°C failed to reveal any changes in the enzyme 
cleavage pattern, all bands showed a similar 
decrease in intensity. In contrast clear differences 
between the drug-treated and control anes are ap- 
parent at 4°C. This effect of temperature probably 
reflects the kinetics of the drug-DNA interaction 
and has been observed for daunomycin [3] as well 
as other small ligands [9]. It is readily apparent that 
the two drugs produce very different footprinting 
patterns. At high concentrations both drugs pro- 
tect all DNA bands form digestion, but at low con- 
centrations a specific pattern is induced in which 
certain bands are protected while others show 
relative enhancements. The results are best ex- 
plained by considering the two drugs separately. 
3.1. Daunomycin 
DNase I footprinting patterns in the presence 
and absence of 2.5/zM daunomycin are presented 
in figs 2 and 3 at 4°C. It is readily apparent that the 
drug has radically altered the enzyme cleavage pat- 
tern and a summary of the major sites of protection 
on the four DNA fragments i presented in table 1. 
It should be noted that at this low temperature 
there are several gaps in the control enzyme 
cleavage pattern, especially at homopolymeric runs 
of A and T, so that if the drug binds to any of these 
regions then it will not be detected; the sites listed 
in table 1 may therefore not include all the binding 
regions. DNase I is known to cut DNA in the minor 
groove and so produces cleavage patterns which 
are staggered by about 3 bonds towards the 
3'-direction. Drug-binding sites should therefore 
be located at the 5'-ends of each of the protected 
regions. No simple consensus recognition sequence 
is apparent from these data, though many of these 
sites contain adjacent GC base pairs. 
3.2. Ditrisarubicin B 
Figs 2 and 3 reveal that at the highest concentra- 
tions ditrisarubicin protects nearly all DNA bonds 
from enzyme cleavage, suggesting that the ligand 
does not possess an absolute sequence binding 
preference. At lower concentrations, however, a 
few discrete bands are missing in each case. These 
are listed in table 1. With 1/zM drug specific bands 
are missing around position 760 on the 220-mer, 65 
and 55 on the 135-mer and 20 on the ptyr2 DNA 
Table 1 
Daunomycin Ditrisarubicin 
tyrT DNA 24-27 (TCATC) 
31-34 (GTAAT) 
56-62 (GTTACGTT) 
19-23 (TGTAGG) 
38-44 (CGCGCATC) 
77-86 (ATAGTGCACGA) 
806-811 (AGGCCGC) 
777-782 (CCGAACA) 
757-760 (CTCCA) 
47-50 (AGCCT) 
55-65 (TGTAAGCCAGGG) 
pTyr2 DNA 
220-mer 
135-mer 
19-25 (ATCCGTAA) 
35-40 (GGTTGCG) 
52-58 (CGTTGAGA) 
19-24 (GTGTAGG) 
759-763 (CCATGC) 
53-58 (GAGGGGA) 
61-65 (TGTAAG) 
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fragment. In each of these instances the rest of the 
cleavage pattern is unaffected. These blockages are 
in different positions to those produced by dauno- 
mycin. As the drug concentration is raised a greater 
number of bands become protected. In contrast to 
daunomycin no drug-induced enhancements are 
apparent. 
4. DISCUSSION 
The results presented show that both daunomy- 
cin and ditrisarubicin B bind to DNA in a sequence 
selective fashion, and that the two drugs display 
different sequence preferences. The data for 
daunomycin are similar to those previously 
reported for the tyrT DNA fragment and are con- 
sistent with drug binding to two contiguous GC 
base pairs flanked by an AT pair. The best binding 
sites for ditrisarubicin often contain the 
dinucleotide step GpT (ApC) and are frequently 
located in regions of alternating purines and 
pyrimidines. In this regard it appears that the 
binding characteristics of ditrisarubicin B are more 
closely related to nogalamycin than daunomycin 
[6,7]. 
The inability of ditrisarubicin B to induce 
enhancements in the DNase I cleavage pattern is 
unusual. Most intercalating ligands increase the 
rate of DNase I cleavage in runs of homopolymeric 
A and T although this does not appear to be the 
case for daunomycin. These enhancements are 
understood as arising from regions of DNA to 
which the drug is not bound and which are struc- 
turally modified by ligand binding to adjacent 
sites. Two possibilities could account for the 
absence of enhancements with ditrisarubicin; either 
the drug does not perturb the DNA structure 
significantly, or more likely it only possesses a
limited selectivity and binds reasonably well to 
those regions which would otherwise be enhanced. 
The different sequence recognition properties of 
ditrisarubicin B were unexpected. It was an- 
ticipated that it should bind to similar regions of 
DNA having a larger binding site size on account of 
the extra sugar residues. The only site where this 
may be observed is around position 20 on ptyr2 
DNA for which daunomycin protects as far as posi- 
tion 23 while the ditrisarubicin footprint extends to 
position 24. Generally the binding regions of the 
two ligands do not overlap. These binding dif- 
ferences may be due to the presence or absence of 
the C13 carbonyl group, the additional bulk pro- 
vided by the trisaccharides, the second charged 
sugar residue or favourable contacts between the 
extra sugar residues and groups on the DNA. Since 
the binding sites for ditrisarubicin are similar to 
those observed for nogalamycin and related an- 
tibiotics [7] which also possess bulky sugar substi- 
tuents it seems likely that the altered sequence 
selectivity arises from the nature of the sugar side 
groups, rather than hydrogen bonding substituents 
on the chromophore. 
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